Immunocore (NASDAQ:IMCR) Insider Leger Tina Amber St Sells 1,000 Shares of Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider Leger Tina Amber St sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $32,350.00. Following the sale, the insider owned 1,119 shares in the company, valued at approximately $36,199.65. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Immunocore Price Performance

Shares of Immunocore stock traded down $0.67 during trading on Friday, hitting $32.50. The stock had a trading volume of 127,005 shares, compared to its average volume of 455,268. The business’s 50-day moving average is $33.89 and its 200 day moving average is $34.30. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -57.02 and a beta of 0.78. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $40.71.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IMCR. Wells Fargo & Company initiated coverage on Immunocore in a report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price objective on the stock. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Morgan Stanley increased their price target on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Mizuho set a $38.00 price objective on shares of Immunocore in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.90.

Immunocore News Roundup

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst coverage and institutional ownership point to upside: several brokers maintain positive outlooks (examples cited include UBS and Wells Fargo) and the consensus average price target remains well above the current price (~$60.90 average target reported), while institutional ownership is high (~84.5%), which can support share stability and long-term demand. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: Immunocore shows very healthy current and quick ratios (~6.00 and ~5.97), which reduces short-term solvency risk but is unlikely to drive near-term share moves by itself. Trading volume today was well below average, which can amplify price moves on news. (No definitive short-interest signal — reported short-interest data appears inconsistent/buggy and should be treated cautiously.)
• Negative Sentiment: Significant insider selling: CEO Bahija Jallal sold 11,474 shares at an average of $32.35 (≈$371k), reducing her stake by ~48%. Multiple other insiders (including David M. Berman, CAO John Goll and Tina Leger) also sold large portions of their holdings on the same day. Such clustered insider dispositions can be read negatively by the market and put downward pressure on the stock. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Institutional Trading of Immunocore

A number of hedge funds have recently modified their holdings of IMCR. Royal Bank of Canada raised its stake in Immunocore by 45.1% during the first quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after buying an additional 13,689 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the period. State of New Jersey Common Pension Fund D purchased a new position in shares of Immunocore during the 2nd quarter valued at about $292,000. Y Intercept Hong Kong Ltd purchased a new stake in Immunocore in the 2nd quarter worth $1,621,000. Finally, Assetmark Inc. increased its holdings in Immunocore by 3.7% in the 2nd quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock valued at $1,097,000 after acquiring an additional 1,248 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.